TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616788547
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Omega-3 + L-carnitine
Study: 616788547
Drug: L-carnitine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine + Omega-3
Study: 35065662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous (IV) phenobarbital (7.5 mg/kg of ideal body weight)
Study: 35065662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching IV placebo
Study: 34400314
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose ICS without use of background controller
Study: 34400314
Drug: As-needed ICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed ICS dosing
Study: 32912290
Drug: Ibudilast (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (50 mg BID)
Study: 33487257
Drug: Regular yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular yogurt (300 g/d)
Study: 32607569
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral hydration (ice chips and water) after extubation
Study: 35498440
Drug: Testosterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (10 mg/day)
Study: 34872283
Drug: 0.05 µg·kg‐1·min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Study: 34872283
Drug: 0.1 µg·kg‐1·min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 µg·kg‐1·min‐1 remifentanil combined with sevoflurane
Study: 34215501
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus tailored exercise training (foam dressing, short-stretch bandage, stretching, resistive, and aerobic exercise sessions, 3 days/week for 12 weeks)
Study: 34215501
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (foam dressing, short-stretch bandage)
Study: 34215501
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus tailored exercise training
Study: 32198520
Drug: Mailed nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed nicotine replacement therapy (NRT)
Study: 36154908
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CBD Isolate
Study: 36154908
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CBD Broad Spectrum
Study: 33707768
Drug: Protein drug
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein drug targets
Study: 33707768
Drug: Drug targets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug targets
Study: 35722465
Drug: rCCK96‐104PE38 targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCCK96‐104PE38 targeted drug
Study: 34533039
Drug: Glutathione infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione infusion (2500 mg/25 mL over 10 minutes, followed by the same doses at 24, 48, and 72 hours)
Study: 35531796
Drug: PN-HPT® (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-HPT® (4 ml intradermally)
Study: 35531796
Drug: Cross-linked hyaluronic
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-linked hyaluronic acid (2 ml subdermally)
Study: 35531796
Drug: Saline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (4 ml intradermally)
Study: 32909076
Drug: ebselen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebselen (600 mg bd)
Study: 35686561
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg once daily for 16 weeks
Study: 33608976
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy for adolescents + brief cognitive intervention to decrease self-criticism
Study: 32866634
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using eosin
Study: 35381840
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (IV group)
Study: 33200626
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg elemental calcium daily until 20 weeks' gestation, then 1.5 g until delivery)
Study: 35829749
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in MRI
Study: 35829749
Drug: Last fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Last fraction of treatment
Study: 35012812
Drug: Phenylephrine 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg
Study: 35012812
Drug: Norepinephrine 8 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 8 μg
Study: 32434847
Drug: PfSPZ-GA1 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-GA1 Vaccine (9.0 × 10^5 PfSPZ)
Study: 32434847
Drug: PfSPZ-GA1 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-GA1 Vaccine (4.5 × 10^5 PfSPZ)
Study: 32434847
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (4.5 × 10^5 PfSPZ)
Study: 32434847
Drug: PfSPZ-GA1 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-GA1 Vaccine (both doses)
Study: 37431294
Drug: asciminib 40
Normalized name: asciminib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: asciminib 40 mg twice daily
Study: 34407542
Drug: bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosutinib 500 mg once daily
Study: 32034814
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) from Fangming Pharmaceutical Group (Test, T)
Study: 32034814
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) from NORVASC® (Reference, R)
Study: 38814433
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Study: 38814433
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Study: 32384434
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut embedding treatment (two weeks at predefined acupuncture points: Shenshu (BL23), Sanyinjiao (SP6), Guanyuan (RN4), Ganshu (BL18), Zusanli (ST36), Pishu (BL20))
Study: 32384434
Drug: Alprazolam tablet
Normalized name: Alprazolam Tablets
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam tablet (0.4 mg, 1 tablet, 3 times a day)
Study: 33706003
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL 300 mg/day
Study: 34654402
Drug: Radiotherapy comprising
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy comprising 25 Gy in 5 fractions with concomitant (150 mg/m2/day, 5 days) and adjuvant temozolomide
Study: 34654402
Drug: Radiotherapy comprising
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy comprising 40 Gy in 15 fractions with concomitant (75 mg/m2/day, every day from first to last day of radiation) and adjuvant temozolomide
Study: 35387783
Drug: BCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCT plus ultrasound guided intra‐articular hip injection of 40 mg triamcinolone acetonide and 4 mL 1% lidocaine
Study: 35387783
Drug: BCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCT plus ultrasound guided intra‐articular hip injection of 5 mL 1% lidocaine
Study: 35387783
Drug: BCT (best
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCT (best current treatment)
Study: 35640099
Drug: Oral-Silent-Oral (OSO)
Normalized name: Silene laciniata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-Silent-Oral (OSO) condition
Study: 35640099
Drug: Silent-Oral (SO)
Normalized name: Silene laciniata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silent-Oral (SO) condition
Study: 35986465
Drug: Phos‐Flur gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phos‐Flur gel (study group)
Study: 32297054
Drug: Laparoscopically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopically guided TAP block with 10 ml of 0.25% bupivacaine at each of the four sites
Study: 33687487
Drug: PB-119 75
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 75 μg
Study: 33687487
Drug: PB-119 150
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 150 μg
Study: 33687487
Drug: PB-119 200
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 200 μg
Study: 35853272
Drug: Pre-operative sublingual
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative sublingual 400mcg misoprostol
Study: 35704338
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content cigarettes (0.4 mg/g nicotine)
Study: 32520577
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion in LPS-challenged volunteers
Study: 32520577
Drug: Higher norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher norepinephrine infusion rates in patients
Study: 32520577
Drug: β-blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker use in patients
Study: 35838942
Drug: Melatonin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.3 mg/kg for < 10 kg, 3 mg for 10-15 kg, 6 mg for > 15 kg)
Study: 35838942
Drug: Triclofos (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclofos (50 mg/kg, max 1 g for 6 mo to 11 y; 2 g for 11 to 18 y)
Study: 34370612
Drug: Nonimmersive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonimmersive virtual reality (VR) intervention associated with conventional therapy
Study: 35999816
Drug: Patient engagement
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient engagement strategies including bi-weekly meetings, newsletters, and educational materials.
Study: 36306132
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g intravenous casirivimab and imdevimab
Study: 36306132
Drug: 8.0 g
Normalized name: PERACETIC ACID 8.0 g in 4000 mL TOPICAL LIQUID [Peraflu D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.0 g intravenous casirivimab and imdevimab
Study: 34519801
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Study: 34519801
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and cisplatin 75 mg/m2)
Study: 35377447
Drug: Lanraplenib 30
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanraplenib 30 mg
Study: 35377447
Drug: Tirabrutinib 40
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirabrutinib 40 mg
Study: 35329211
Drug: Weekly content
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly content with customised behaviour change techniques (experimental group)
Study: 32667902
Drug: Saline consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline consumption (423 mL of normal saline, sodium 154 mmol/L)
Study: 33622669
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg TTP399
Study: 33464300
Drug: Atabecestat 25
Normalized name: Atabecestat
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atabecestat 25 mg
Study: 33464300
Drug: Atabecestat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atabecestat (5 mg and 25 mg)
Study: 33464300
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after stopping treatment
Study: 35584268
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with splint (40 mg methylprednisolone + 0.5 ml lidocaine, splint worn full time for 3 months)
Study: 35584268
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection without splint (40 mg methylprednisolone + 0.5 ml lidocaine)
Study: 35027324
Drug: HAI-ox with
Normalized name: OX BILE
DrugBank: Ox bile extract (DB14016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI-ox with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Study: 35027324
Drug: Systemic oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic oxaliplatin with FOLFOX + targeted therapy or FOLFOXIRI + bevacizumab
Study: 34271948
Drug: Multifactorial intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intensive therapy (MT)
Study: 35274344
Drug: Home-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based oral exercises (tongue-strengthening, oral diadochokinesis, mouth-opening exercises) for 3 months
Study: 35274344
Drug: Advice on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice on oral health care (Control group)
Study: 34936272
Drug: Wangbuliuxing decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wangbuliuxing decoction (oral administration, twice a day for 7 days) combined with massage at breast and acupoint (Zhongfu [LU 1], Yunmen [LU 2], Danzhong [CV 17], 2 min per acupoint, twice a day for 7 days)
Study: 35002228
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of BMMC and ADSC
Study: 32660542
Drug: Moxidectin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (24 μg/kg) for four or six monthly doses
Study: 32660542
Drug: Heartgard® Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heartgard® Plus (ivermectin/pyrantel) for six monthly doses
Study: 32660542
Drug: Interceptor® Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interceptor® Plus (milbemycin oxime/praziquantel) for six monthly doses
Study: 33180306
Drug: One-level RDL
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-level RDL reductions achieved by 84% of patients at the end of treatment; 84.9% maintained reduction at 3-year follow-up.
Study: 33180306
Drug: Two-level RDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-level RDL reductions achieved by 68% of patients at the end of treatment; 77.7% maintained reduction at 3-year follow-up.
Study: 35617452
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel applied every night (control)
Study: 34471992
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg every 4 weeks (Q4W)
Study: 34471992
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (weekly until Week 4, then Q4W)
Study: 33290813
Drug: Heparin locking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin locking
Study: 33290813
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (SQH) 7,500 units TID
Study: 33290813
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (SQH) 5,000 units
Study: 33290813
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (SQH) 7,500 units vs 5,000 units
Study: 34842135
Drug: Antidepressant continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant continuation (maintenance group)
Study: 34842135
Drug: Antidepressant discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant discontinuation (discontinuation group)
Study: 34008144
Drug: Colchicine and
Normalized name: colchicine and probenecid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs)
Study: 32892655
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg tablet (formulation 1)
Study: 32892655
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg tablet (formulation 2)
Study: 35667420
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with hyaluronic acid gel
Study: 35972817
Drug: Ribociclib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (400 mg) combined with weekly carboplatin and paclitaxel chemotherapy followed by ribociclib maintenance
Study: 36197167
Drug: Humidified low-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified low-flow oxygen therapy
Study: 36197167
Drug: Nonhumidified low-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhumidified low-flow oxygen therapy
Study: 34781363
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 or 2 g/kg
Study: 32114905
Drug: Therapy Component
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy Component Checklist (TCC)
Study: 35435472
Drug: veliparib 400
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: veliparib 400 mg BID
Study: 35435472
Drug: veliparib 50-500
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: veliparib 50-500 mg BID
Study: 34196106
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic preconditioning (RIPC) - 3 × 5 min administration of 200 mmHg sphygmomanometer on the arm (n=31)
Study: 34196106
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n=29)
Study: 33152965
Drug: Fentanyl 1–2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1–2 μg/kg
Study: 33152965
Drug: Fentanyl 6–7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 6–7 μg/kg
Study: 36052684
Drug: ACE-inhibitor+thiazide
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor+thiazide
Study: 36052684
Drug: CCB+ACE-inhibitor
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB+ACE-inhibitor
Study: 35482348
Drug: Primary RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary RT (60 Gy of RT with concurrent weekly cisplatin in node-positive patients)
Study: 35482348
Drug: TOS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOS and neck dissection (ND) with adjuvant reduced-dose RT depending on pathologic findings
Study: 34488362
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CT) - TESSYS technique under spinal endoscopy + drug therapy (coenzyme A, adenosine triphosphate, 10% glucose injection, 10% potassium chloride, vitamin B6, vitamin B12, dexamethasone, 20% mannitol, traditional Chinese medicine)
Study: 34488362
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CT)
Study: 33561312
Drug: Panitumumab 6
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 6 mg/kg
Study: 33561312
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg
Study: 33106183
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Interferon beta-1a + lopinavir/ritonavir (Kaletra)
Study: 33106183
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Interferon beta-1a + lopinavir/ritonavir (Kaletra)
Study: 32339169
Drug: Capacitive resistive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive resistive radiofrequency therapy (RF)
Study: 35395957
Drug: Hydroxychloroquine, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, twice daily for 14 days
Study: 35395957
Drug: Lopinavir/ritonavir, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir, twice daily for 14 days
Study: 36271391
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine drug treatment: NSAIDs & Anti TNF)
Study: 33515503
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice a day orally for six cycles of 28 days or until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study: 35059823
Drug: Arthroscopic debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic debridement of dorsal capsule injuries during primary surgery
Study: 35059823
Drug: No debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No debridement of dorsal capsule injuries during primary surgery
Study: 32196954
Drug: Levocetirizine oral
Normalized name: levocetirizine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine oral disintegrating tablet (ODT) 5 mg
Study: 32196954
Drug: Levocetirizine immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine immediate-release tablet (IRT) 5 mg